7.60
+0.57(+8.11%)
Currency In USD
| Previous Close | 7.03 |
| Open | 7.13 |
| Day High | 7.63 |
| Day Low | 6.93 |
| 52-Week High | 8.9 |
| 52-Week Low | 3.68 |
| Volume | 247,403 |
| Average Volume | 178,882 |
| Market Cap | 279.89M |
| PE | 58.46 |
| EPS | 0.13 |
| Moving Average 50 Days | 6.56 |
| Moving Average 200 Days | 5.84 |
| Change | 0.57 |
If you invested $1000 in Lifecore Biomedical, Inc. (LFCR) 10 years ago, it would be worth $535.21 as of December 26, 2024 at a share price of $7.6. Whereas If you bought $1000 worth of Lifecore Biomedical, Inc. (LFCR) shares 5 years ago, it would be worth $654.61 as of December 26, 2024 at a share price of $7.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
GlobeNewswire Inc.
Dec 19, 2024 9:05 PM GMT
Webcast Scheduled for Thursday, January 2 at 4:30 p.m. EasternCHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), t
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
GlobeNewswire Inc.
Dec 19, 2024 12:00 PM GMT
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum’s NIH-Funde
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
GlobeNewswire Inc.
Nov 26, 2024 9:05 PM GMT
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position Builds Upon Other Recent Strategic Financial Activities, including $24.3 Million PI